Unknown

Dataset Information

0

Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance.


ABSTRACT: The aim of this study was to profile the spectrum of genetic mutations in acute myeloid leukemia (AML) patients co-occurring with CEBPA double mutation (CEBPAdm). Between January 1, 2012, and June 30, 2017, 553 consecutive patients with de novo AML were screened for CEBPA mutations. Out of these, 81 patients classified as CEBPAdm were analyzed further by a sensitive next-generation sequencing assay for mutations in 112 candidate genes. Within the CEBPA gene itself, we found 164 mutations. The most common mutated sites were c.936_937insGAG (n = 11/164, 6.71%) and c.939_940insAAG (n = 11/164, 6.71%), followed by c.68dupC (n = 10/164, 6.10%). The most common co-occurring mutations were found in the CSF3R (n = 16/81, 19.75%), WT1 (n = 15/81, 18.52%), and GATA2 (n = 13/81, 16.05%) genes. Patients with CSF3R mutations had an inferior four-year relapse-free survival (RFS) than those with the wild-type gene (15.3% versus 46.8%, respectively; P = 0.021). Patients with WT1 mutations had an inferior five-year RFS compared with those without such mutations (0% versus 26.6%, respectively, P = 0.003). However, GATA2, CSF3R, WT1 mutations had no significant influence on the overall survival. There were some differences in the location of mutational hotspots within the CEBPA gene, as well as hotspots of other co-occurring genetic mutations, between AML patients from Chinese and Caucasian populations. Some co-occurring mutations may be potential candidates for refining the prognoses of AML patients with CEBPAdm in the Chinese population.

SUBMITTER: Su L 

PROVIDER: S-EPMC5982761 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mutational spectrum of acute myeloid leukemia patients with double <i>CEBPA</i> mutations based on next-generation sequencing and its prognostic significance.

Su Long L   Tan YeHui Y   Lin Hai H   Liu XiaoLiang X   Yu Li L   Yang YanPing Y   Liu ShanShan S   Bai Ou O   Yang Yan Y   Jin FengYan F   Sun JingNan J   Liu ChunShui C   Liu QiuJu Q   Gao SuJun S   Li Wei W  

Oncotarget 20180103 38


The aim of this study was to profile the spectrum of genetic mutations in acute myeloid leukemia (AML) patients co-occurring with <i>CEBPA</i> double mutation (<i>CEBPA</i><sup>dm</sup>). Between January 1, 2012, and June 30, 2017, 553 consecutive patients with <i>de novo</i> AML were screened for <i>CEBPA</i> mutations. Out of these, 81 patients classified as <i>CEBPA</i><sup>dm</sup> were analyzed further by a sensitive next-generation sequencing assay for mutations in 112 candidate genes. Wit  ...[more]

Similar Datasets

| S-EPMC9367218 | biostudies-literature
| S-EPMC5077997 | biostudies-literature
| S-EPMC7666719 | biostudies-literature
| S-EPMC8427751 | biostudies-literature
| S-EPMC8753195 | biostudies-literature
| S-EPMC6016334 | biostudies-literature
| S-EPMC3364462 | biostudies-literature
| S-EPMC6471684 | biostudies-literature
| S-EPMC5436901 | biostudies-literature
| S-EPMC5389788 | biostudies-literature